These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 35216036)

  • 1. Collection of Monoclonal Antibodies Targeting SARS-CoV-2 Proteins.
    Pribanić Matešić M; Kučan Brlić P; Lenac Roviš T; Mačak Šafranko Ž; Chaouat AE; Miklić K; Malić S; Ivanković N; Schubert M; Bertoglio F; Markotić A; Mandelboim O; Jonjić S; Brizić I
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35216036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?
    Mohammed MEA
    Curr Mol Med; 2022; 22(1):50-66. PubMed ID: 33622224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of Murine Hybridoma Cells Producing Antibodies against Spike Protein of SARS-CoV-2.
    Antipova NV; Larionova TD; Siniavin AE; Nikiforova MA; Gushchin VA; Babichenko II; Volkov AV; Shakhparonov MI; Pavlyukov MS
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses.
    Kumar R; Christensen ND; Kaddis Maldonado RJ; Bewley MC; Ostman A; Sudol M; Chen EC; Buchkovich NW; Gontu A; Surendran Nair M; Nissly RH; Minns AM; Kapur V; Rossi R; Kuchipudi SV; Lindner SE; Parent LJ; Flanagan JM; Buchkovich NJ
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins.
    Li Y; Xu Z; Lei Q; Lai DY; Hou H; Jiang HW; Zheng YX; Wang XN; Wu J; Ma ML; Zhang B; Chen H; Yu C; Xue JB; Zhang HN; Qi H; Guo SJ; Zhang Y; Lin X; Yao Z; Sheng H; Sun Z; Wang F; Fan X; Tao SC
    Cell Rep; 2021 Jul; 36(2):109391. PubMed ID: 34242574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
    Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
    Front Immunol; 2021; 12():793953. PubMed ID: 34899762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
    Rattanapisit K; Shanmugaraj B; Manopwisedjaroen S; Purwono PB; Siriwattananon K; Khorattanakulchai N; Hanittinan O; Boonyayothin W; Thitithanyanont A; Smith DR; Phoolcharoen W
    Sci Rep; 2020 Oct; 10(1):17698. PubMed ID: 33077899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of immunodominant epitopes on nucleocapsid and spike proteins of the SARS-CoV-2 in Iranian COVID-19 patients.
    Maghsood F; Shokri MR; Jeddi-Tehrani M; Torabi Rahvar M; Ghaderi A; Salimi V; Kardar GA; Zarnani AH; Amiri MM; Shokri F
    Pathog Dis; 2022 Feb; 80(1):. PubMed ID: 34994386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody.
    Terry JS; Anderson LB; Scherman MS; McAlister CE; Perera R; Schountz T; Geiss BJ
    Virology; 2021 Jun; 558():28-37. PubMed ID: 33714753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes.
    Fu D; Zhang G; Wang Y; Zhang Z; Hu H; Shen S; Wu J; Li B; Li X; Fang Y; Liu J; Wang Q; Zhou Y; Wang W; Li Y; Lu Z; Wang X; Nie C; Tian Y; Chen D; Wang Y; Zhou X; Wang Q; Yu F; Zhang C; Deng C; Zhou L; Guan G; Shao N; Lou Z; Deng F; Zhang H; Chen X; Wang M; Liu L; Rao Z; Guo Y
    PLoS Biol; 2021 May; 19(5):e3001209. PubMed ID: 33961621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein-ACE2 interaction.
    Yuan M; Wan Y; Liu C; Li Y; Liu Z; Lin C; Chen J
    Cell Mol Immunol; 2021 Jun; 18(6):1562-1564. PubMed ID: 33958745
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2.
    Lapuente D; Maier C; Irrgang P; Hübner J; Peter AS; Hoffmann M; Ensser A; Ziegler K; Winkler TH; Birkholz T; Kremer AE; Steininger P; Korn K; Neipel F; Überla K; Tenbusch M
    Eur J Clin Microbiol Infect Dis; 2021 Apr; 40(4):751-759. PubMed ID: 33078221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody.
    Dangi T; Sanchez S; Class J; Richner M; Visvabharathy L; Chung YR; Bentley K; Stanton RJ; Koralnik IJ; Richner JM; Penaloza-MacMaster P
    J Clin Invest; 2022 Dec; 132(23):. PubMed ID: 36219482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19.
    Asdaq SMB; Rabbani SI; Alkahtani M; Aldohyan MM; Alabdulsalam AM; Alshammari MS; Alajlan SA; Binrokan A; Mohzari Y; Alrashed A; Alshammari MK; Imran M; Nayeem N
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues.
    Szabolcs M; Sauter JL; Frosina D; Geronimo JA; Hernandez E; Selbs E; Rapkiewicz AV; Rekhtman N; Baine MK; Jäger E; Travis WD; Jungbluth AA
    Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):5-12. PubMed ID: 33086222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19.
    Casadevall A; McConnell S; Focosi D
    Expert Opin Biol Ther; 2024 Aug; 24(8):787-797. PubMed ID: 39088242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.